Simcere reports 15% revenue growth in first half

Simcere Pharmaceutical Group reported revenue of RMB3,585 million for the six months ended June 30, 2025, up 15.1% from RMB3,114 million in 2024. Revenue from innovative pharmaceuticals grew 26.0% to RMB2,776 million, representing 77.4% of total revenue.

Profit attributable to equity shareholders increased 32.2% to RMB604 million. The group's research and development spending jumped 68.0% to RMB1,028 million.

Key approvals included QUVIVIQ and ENZESHU for marketing, with NDA acceptance for Deunoxavir Marboxil Tablets and Rademikibart. The company expanded its R&D pipeline to over 60 innovative drugs.